OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+11.44%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$46.1M
AUM Growth
+$46.1M
(-3.3%)
Cap. Flow
-$2.17M
Cap. Flow
% of AUM
-4.72%
Top 10 Holdings %
Top 10 Hldgs %
52.4%
Holding
52
New
2
Increased
15
Reduced
16
Closed
2
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$3.26M |
| 2 |
MEI Pharma
MEIP
|
$1.58M |
| 3 |
Exelixis
EXEL
|
$292K |
| 4 |
Incyte
INCY
|
$69.9K |
| 5 |
Alkermes
ALKS
|
$50.2K |
Top Sells
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$5.37M |
| 2 |
Nektar Therapeutics
NKTR
|
$728K |
| 3 |
Karyopharm Therapeutics
KPTI
|
$671K |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$327K |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$281K |
Sector Composition
| 1 | Healthcare | 70.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.52M | 11.97% | 58,000 +34,200 | +144% | +$3.26M |
|
|
2
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $5.37M | 11.64% | 93,805 -93,805 | -50% | -$5.37M |
|
3
Mettler-Toledo International
MTD
$26.8B
| $2.08M | 4.51% | 3,594 | – | – |
|
4
iShares Biotechnology ETF
IBB
$5.6B
| $2.06M | 4.47% | 18,750 | – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1.71M | 3.7% | 13,734 -119 | -0.9% | -$14.8K |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $1.59M | 3.44% | 9,331 +107 | +1% | +$18.2K |
|
|
7
MEI Pharma
MEIP
$160M
| $1.58M | 3.42% | +400,000 | New | +$1.58M |
|
8
Illumina
ILMN
$15.8B
| $1.5M | 3.24% | 5,352 -154 | -3% | -$43K |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.39M | 3.01% | 14,112 +432 | +3% | +$42.6K |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.38M | 3% | 20,834 -292 | -1% | -$19.4K |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $1.33M | 2.89% | 15,833 -169 | -1% | -$14.2K |
|
|
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
| $1.2M | 2.6% | 6,900 | – | – |
|
13
Qiagen
QGEN
$10.1B
| $1.18M | 2.57% | 32,720 -445 | -1% | -$16.1K |
|
14
FibroGen
FGEN
$47.8M
| $1.15M | 2.5% | 18,423 +142 | +0.8% | +$8.89K |
|
15
ProQR Therapeutics
PRQR
$237M
| $1.12M | 2.44% | 153,846 | – | – |
|
16
Amgen
AMGN
$155B
| $1.1M | 2.37% | 5,930 +125 | +2% | +$23.1K |
|
|
17
Alkermes
ALKS
$4.78B
| $1.05M | 2.28% | 25,552 +1,219 | +5% | +$50.2K |
|
18
Biogen
BIIB
$19.4B
| $1.03M | 2.22% | 3,532 +15 | +0.4% | +$4.35K |
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $997K | 2.16% | 23,916 +783 | +3% | +$32.6K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $974K | 2.11% | 10,336 -320 | -3% | -$30.2K |
|
21
Regeneron Pharmaceuticals
REGN
$61.5B
| $931K | 2.02% | 2,698 +76 | +3% | +$26.2K |
|
|
22
Incyte
INCY
$16.5B
| $826K | 1.79% | 12,321 +1,043 | +9% | +$69.9K |
|
|
CELG
23
DELISTED
Celgene Corp
CELG
| $772K | 1.67% | 9,724 +212 | +2% | +$16.8K |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $591K | 1.28% | 13,000 | – | – |
|
|
TSRO
25
DELISTED
TESARO, Inc.
TSRO
| $511K | 1.11% | 11,500 | – | – |
|